Ecolectro, Inc.

Ecolectro develops structurally robust and highly conductive polymer membranes for a range of applications, including electrolysis and fuel cell systems that not only improve performance but also dramatically decrease costs.

Lumendi AG

Lumendi Ltd., is focused on the development of new minimal invasive surgical tools and devices that will provide solutions for minimally invasive gastrointestinal surgeries. The company’s first product is an add-on to any commercially available endoscope that will avoid invasive colon resections to treat more complex gastrointestinal diseases.

Embark Veterinary, Inc.

Embark is a veterinary science-focused company specializing in canine genetics. Through the use of cutting-edge genetic testing and analysis, Embark offers 21st century pet wellness advice coupled with comprehensive ancestry, morphological trait, and genetic disease information for dog owners.

XyloCor Therapeutics, Inc.

XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.

CycloPure, Inc.

CycloPure is engaged in the design, development, and commercialization of a new class of highly adsorbent materials for use in the separation and removal of pollutants, VOCs, and other organic compounds from water and air. The technology was partly developed by the Helbling Research Group at The School of Civil and Environmental Engineering. CycloPure has raised $8.81M in funding to date.

Conamix, Inc.

Conamix is commercializing high performance battery materials based on proprietary Cornell technology. The company’s unique battery materials allow higher energy density in existing lithium ion architectures and are manufactured using low cost and highly commercial methods.

Annapurna Therapeutics Limited

Annapurna Therapeutics is a gene therapy company focused on discovering and developing new therapeutic products for people living with severe diseases. Annapurna’s product pipeline includes programs for alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), the cardiomyopathy associated with Friedreich’s ataxia and severe allergy. Annapurna Therapeutics was acquired by Avalanche Biotechnologies, Inc. in 2016.

Lumidyne Technologies, LLC

Lumidyne develops next-generation fluorescent probes exhibiting superior brightness and stability compared with current commercially available reagents.

ZYMtronix, Inc.

ZYMtronix is a biotechnology startup that services enzyme and pharmaceutical manufacturers. ZYMtronix immobilizes and optimizes biocatalysts for continuous manufacturing using green chemistry principles to lower the costs and increase the yields of drug manufacturing.